AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$ENOV

Enovis Corp (ENOV) Q3 2026 Earnings Call Transcript

Enovis Corp (ENOV) reported Q3 2026 sales of $559M, up 2% YoY and 5% organically. Recon grew 6% organically, with extremities up 8% and hips/knees up 5%. P&R grew 3% organically. Adjusted EBITDA margin was 18.5%, up 120 bps YoY. The company raised full-year revenue and EPS guidance, announcing a $200M share repurchase program. Enovis expects to complete the acquisition of Essential Robotics by year-end, aiming to bring a knee robot to market within 2 years.

Original reporting
finance.yahoo.com
Published Nov 5, 2026, 8:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 8:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Enovis Corp (ENOV) Q3 2026 Earnings Call Transcript — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$ENOVBullishHigh
01

Why it matters

The earnings beat and new share repurchase program are fresh information that can move the stock.

02

Market read

Earnings and guidance update are primary drivers for ENOV's near‑term price action.

03

What to watch

Geopolitical tension in the Middle East may pressure international growth despite guidance.

Relevance 8/10Novelty 8/10Timing: after-hours

Background

Enovis Corp held its Q3 2026 earnings call, providing detailed financial results and forward guidance.

Company-level read

Ticker impact

$ENOVBullishHigh confidence
Context

Q3 2026 earnings disclosed: $559M sales, $0.88 EPS, raised full-year guidance and announced $200M share repurchase.

Expected impact

likely upward pressure as market prices in higher earnings and buyback.

Evidence & confidence

Earnings beat, EPS up 17%, and new buyback program provide fresh positive catalyst.

Market effects

Sector

Positive for medical device sector as Enovis signals growth in orthopedics and robotics.

Regional

U.S. market may see modest lift in healthcare stocks.

Global

Limited to investors tracking U.S. med‑tech equities.

Counterpoint

What could challenge this read

If integration risks from the Essential Robotics acquisition materialize, upside could be limited.

Key entities

  • Company
    Enovis Corp

    Medical device manufacturer reporting Q3 results.

  • Company
    Essential Robotics

    Target of Enovis acquisition pending close.

Read at source← All news

StoryEnovis raises FY 2026 EPS guidance, authorizes $200 million buyback and plans eCential Robotics acquisition

Also covered by

3 outlets

Related articles

$ENOVHighAI 8/10

Enovis Corp (ENOV) Q3 2026 Earnings Call Highlights: Organic Growth of 5%, Raised Guidance

Enovis Corp (ENOV) reported Q3 2026 organic growth of 5%, raising guidance. U.S. hip and knee growth lagged at 3%, while international markets faced challenges. Adjusted gross margin declined due to mix and inflation. Q4 guidance includes R&D investments and currency impacts. Foot and ankle growth was softer but expected to rebound. Leverage will increase to ~3.4x post-eCential acquisition. Management remains optimistic about market share gains and enabling technology.

finance.yahoo.com
$ENOVMedAI 8/10

Enovis Corporation Q3 2026 Earnings Call Summary

Enovis Corporation reported Q3 2026 earnings, highlighting strong commercial execution and market share gains, particularly with the Nebula stem. The company faces market volatility but is strategically positioned in the ASC channel. International recon business grew 8% organically, led by shoulders. Guidance for Q4 includes modest growth acceleration and a $4 million investment in R&D. The company reaffirmed its 2026 free cash flow target and plans a $200 million share repurchase program.

finance.yahoo.com
$ENOVMed

Enovis earnings beat by $0.11, revenue topped estimates

Enovis (ENOV) reported Q3 EPS of $0.88, beating estimates by $0.11, with revenue at $558.72M, slightly above expectations. The company guided FY 2026 EPS to $3.52-$3.73 and revenue to $2.32B-$2.35B, both below consensus. ENOV stock is down 8.23% over 3 months and 14.07% over 12 months, with 11 negative EPS revisions in the last 90 days.

investing.com